Journal
JOURNAL OF NEUROCHEMISTRY
Volume 90, Issue 5, Pages 1251-1257Publisher
WILEY
DOI: 10.1111/j.1471-4159.2004.02600.x
Keywords
aminopeptidase-A and -N; angiotensin II and IV; extracellular dopamine; insulin-regulated aminopeptidase; striatum
Categories
Ask authors/readers for more resources
The effect of angiotensin (Ang) IV, an inhibitor of insulin-regulated aminopeptidase (IRAP), on extracellular dopamine levels in the striatum of freely moving rats was examined using in vivo microdialysis. The Ang IV was administered locally in the striatum through the microdialysis probe. A concentration-dependent (10-100 muM) increase in extracellular striatal dopamine was observed. The effect of Ang II (10-100 muM), which has only a weak affinity for IRAP, was similar to that observed for Ang IV. The effects of both peptides could not be blocked by the AT(1) antagonist candesartan (10 nM and 1 muM) nor by the AT(2) antagonist S-(+)-1-([4-(dimethylamino)-3-methylphenyl]methyl)-5-(diphenyl-acetyl)-4,5,6,7-tetrahydro-1H-amidazo(4,5-c) pyridine-6-carboxylic acid (1 muM), suggesting that the observed effects are both AT(1) and AT(2) independent. The effect of Ang II could be blocked by the aminopeptidase-A inhibitor (S)-3-amino-4-mercaptobutylsulphonic acid as well as the aminopeptidase-N inhibitor 2-amino-4-methylsulphonylbutane thiol, indicating that the effect of Ang II is mediated via metabolism into Ang IV. Other IRAP inhibitors, such as Divalinal-Ang IV and LVV-haemorphin-7, had similar effects on extracellular dopamine levels as compared with Ang IV. We propose a role for IRAP as mediator for the effects of Ang IV and related peptides on extracellular dopamine levels in the striatum of the rat.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available